Jens-Ole Bock is managing the fast growing CRO, COBO Technologies, that support the growing need for more quality control in genome editing. Focus is InDel mutation analysis and Proteomic profiling. In addition Bock is advisor for the CRISPR Medicine Blog, that post weekly interviews from the CRISPR medicine field. Bock comes with a solid background in molecular biology from the University of Copenhagen, Denmark. He has more than 18 years of commercial experience working with some of the leading genome-editing companies in the world. Bock successfully introduced the first commercially available genome editing tool, the Zinc Finger Nuclease (ZFN), in Europe as part of the specialist team at Sigma-Aldrich. He has done more than 100 presentations at conferences, seminars, and meetings in Europe, the US, and Asia. Jens-Ole Bock also supports the Danish start-up environment as an advisor and as a board member.
Over the past few years, CRISPR has revolutionized the life sciences. Engineered to generate targeted DNA breaks, various DNA changes can be introduced in living organisms which offer the opportunity to treat a plethora of inherited diseases. The ongoing expansions of the CRISPR toolbox supports new applications across various domains of research and medicine. This session intends to provide an informative summary of latest breakthroughs with a focus on recent achievements and potential utility at the clinical setting. The discussion will also include challenges and needs to fully appreciate the potential of this technology.